BioNote Inc
KRX:377740
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3 985
6 080
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
BioNote Inc
Total Current Liabilities
BioNote Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioNote Inc
KRX:377740
|
Total Current Liabilities
₩10.8B
|
CAGR 3-Years
-61%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Total Current Liabilities
₩2.5T
|
CAGR 3-Years
37%
|
CAGR 5-Years
33%
|
CAGR 10-Years
16%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Total Current Liabilities
₩135.6B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Total Current Liabilities
₩52.1B
|
CAGR 3-Years
11%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Total Current Liabilities
₩85.6B
|
CAGR 3-Years
33%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Total Current Liabilities
₩107.6B
|
CAGR 3-Years
13%
|
CAGR 5-Years
73%
|
CAGR 10-Years
N/A
|
|
BioNote Inc
Glance View
BioNote, Inc. develops veterinary diagnostic composition. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2022-12-22. The firm is engaged in the manufacture and sale of rapid diagnostic kits for humans, diagnosis raw materials such as antigens, antibody cell lines, standards, enzymes and others as well as semi-finished products. The firm is also engaged in the manufacture and sale of rapid immunochemical diagnosis, enzyme immune rebound protein, immunochemical fluorescence diagnosis and other products used for animals.
See Also
What is BioNote Inc's Total Current Liabilities?
Total Current Liabilities
10.8B
KRW
Based on the financial report for Dec 31, 2023, BioNote Inc's Total Current Liabilities amounts to 10.8B KRW.
What is BioNote Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 3Y
-61%
Over the last year, the Total Current Liabilities growth was -78%. The average annual Total Current Liabilities growth rates for BioNote Inc have been -61% over the past three years .
You don't have any saved screeners yet
